ArticleACS medicinal chemistry letters2024
Invention of VH-937, a Potent HIV-1 Maturation Inhibitor with the Potential for Infrequent Oral Dosing in Humans.
Abstract read
In one paragraph
Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mechanisms of HIV-1 assembly, release and maturation.Nature reviews. Microbiology · 2026Review
- Structural Basis for HIV-1 Maturation Inhibition by PF-46396 Determined by MAS NMR.Journal of the American Chemical Society · 2025Article
- A Data-Driven Perspective on Bioisostere Evaluation: Mapping the Benzene Bioisostere Landscape with BioSTAR.Journal of medicinal chemistry · 2025Review
- Selected Pentacyclic Triterpenoids and Their Derivatives as Biologically Active Compounds.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Sing-Yuen SitDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Yan ChenDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Jie ChenDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Brian L VenablesDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Jacob J SwidorskiDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Li XuDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.ORCID https://orcid.org/0000-0001-6294-4873
Ny SinDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Richard A HartzDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.ORCID https://orcid.org/0000-0002-3880-6646
Zeyu LinDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Sharon ZhangDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Zhufang LiDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Dauh-Rurng WuDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Peng LiDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
James KempsonDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Xiaoping HouDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.ORCID https://orcid.org/0000-0001-6169-3443
Yoganand ShanmugamDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Dawn ParkerDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Susan JenkinsDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Jean SimmermacherDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Paul FalkDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Brian McAuliffeDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Mark CockettDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Umesh HanumegowdaDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Ira DickerDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Mark KrystalDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
Nicholas A MeanwellDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.ORCID https://orcid.org/0000-0002-8857-1515
Alicia Regueiro-RenDepartments of Discovery Chemistry, Virology, Pharmaceutical Candidate Optimization, and Discovery Synthesis, Bristol Myers Squibb Research and Early Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.ORCID https://orcid.org/0000-0003-2991-719X
Funding
No grant is acknowledged in the PubMed record.
Abstract
Newer generation HIV-1 maturation inhibitors have proven to be viable antiretroviral agents in the clinic. VH3739937, (VH-937,
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.